[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354988-105":59,"doc-detail-354988-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mdx-2001101-study-protocol-a-phase-iiia-multicenter-first-in-human-open-label-clinical-trial-evaluating-mdx2001-monotherapy-in-patients-with-advanced-solid-tumors","MDX-2001–101 study protocol - a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors","","MDX2001 is a tetraspecific T-cell engager-expander antibody engineered to recognize four antigens: c-MET and TROP2 to direct T cells to tumor cells, CD3 to activate T cells, and CD28 to enhance survival and proliferation. Nonclinical studies showed strong antitumor activity across multiple tumor types. The MDX-2001–101 protocol evaluates safety, tolerability, and antitumor effects in advanced solid tumors using phased dose escalation and expansion in a multicenter, open-label design.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mdx-2001101-study-protocol-a-phase-iiia-multicenter-first-in-human-open-label-clinical-trial-evaluating-mdx2001-monotherapy-in-patients-with-advanced-solid-tumors/354988/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mdx-2001101-study-protocol-a-phase-iiia-multicenter-first-in-human-open-label-clinical-trial-evaluating-mdx2001-monotherapy-in-patients-with-advanced-solid-tumors/354988.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is MDX2001 and how does it work?","Question",{"text":112,"@type":113},"MDX2001 is a tetraspecific T-cell engager-expander antibody designed to bind c-MET and TROP2 on tumor cells, CD3 to activate T cells, and CD28 to support T-cell survival and proliferation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the purpose of the MDX-2001–101 trial?",{"text":117,"@type":113},"The trial protocol evaluates the safety, tolerability, and antitumor effects of MDX2001 monotherapy in patients with advanced solid tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How are the trial phases organized (phase Ia, Ib, and IIa)?",{"text":121,"@type":113},"Phase Ia uses Bayesian-guided dose escalation to determine dosing for further study. Phase Ib expands dosing across up to two doses and multiple solid tumor types, and Phase IIa tests effects in patients at the selected doses and tumor types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354988,1790239291,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":8,"preview_urls":144},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 3, 305–312  \n[https://doi.org/10.1080/14796694.2025.2610468](https://doi.org/10.1080/14796694.2025.2610468)  \n| CLINICAL TRIAL PROTOCOL   \u003Cbr>MDX-2001–101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors\u003Cbr>Ecaterina Dumbravaa, Anna Minchomb, Jason Henryc, Melissa Johnsond, David Sommerhaldere, Jaime Merchanf, Rebecca Heistg, Elena Garralda Cabanash, Monette Cotreaui, Anne-Laure Goenagaj, Dalia Burzynj, Lukas Makrisk, Kerry Culmj and Giovanni Abbadessaj\u003Cbr>aDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; bDrug Development Phase 1 Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, UK; cDenver Drug Deveopment Unit, Sarah Cannon Research Institute at Healthone, Denver, CO, USA; dLung Cancer Research, Sarah Cannon Research Institute, Nashville, TN, USA; eSan Antonio Team, NEXT Oncology, San Antonio, TX, USA; fDepartment of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA; gHarvard Medical School, Massachusetts General Hospital, Boston, MA, USA; hBarcelona Team, NEXT Oncology, Barcelona, Spain; iMMC Biopartners, Rye, NH, USA; jModeX Therapeutics, An OPKO Health Company, Weston, MA, USA; kStathmi, Inc., New Hope, PA, USA |  |  |\n| --- | --- | --- |\n| ABSTRACT\u003Cbr>MDX2001 is a tetraspecific T-cell engager-expander antibody engineered to recognize four distinct antigens: cellular mesenchymal-epithelial transition factor (c-MET) and trophoblast antigen 2 (TROP2) to direct T cells to tumor cells, CD3 to activate T cells, and CD28 to enhance T-cell survival and proliferation. MDX2001 has demonstrated potent antitumor activity in nonclinical studies over a wide range of tumor types. Here, we present the protocol design for study MDX-2001–101, a multicenter, open-label, phase I/IIa clinical trial designed to evaluate the safety, tolerability, and antitumor effects of MDX2001 inpatients with advanced solid tumors. The study comprises a phase Ia dose escalation guided by a Bayesian optimal interval design with a targeted maximum tolerated dose toxicity rate of 30%, a phase Ib dose expansion, and a phase IIa indication expansion.\u003Cbr>PLAIN LANGUAGE SUMMARY\u003Cbr>Researchers are looking for better treatments for advanced cancer. This article discusses a clinical trial to learn more about MDX2001, an experimental treatment for advanced cancer. MDX2001 was developed to find cancer cells by identifying proteins on their cell surface and activate the body’s immune system to kill these cancer cells. Cancer treatments that work by boosting the immune system in this way are called immunotherapies. This trial of MDX2001 as a possible treatment for different types of advanced cancer will include people who have solid tumors – clumps of cancer cells that form in the body. The trial will be performed in multiple phases: phase Ia, phase Ib, and phase IIa. During phase Ia, researchers will study different doses of MDX2001 in small groups of patients. The results from phase Ia will help researchers learn which doses should be studied further and who should take part in phase Ib. During phase Ib, researchers will study the effects of 2 doses of MDX2001 in up to 3 different types of solid tumor cancer. The results from phase Ib will help researchers identify which dose(s) and tumor type(s) should be studied further in phase IIa. In phase IIa, researchers will study the effects of MDX2001 in patients with cancer types and at the doses identified in phase Ib. Overall, the main goal of this study is to learn about the safety, tolerability, and anticancer effects of MDX2001 in patients with advanced solid tumors.\u003Cbr>Clinical Trial Registration: NCT06239194 ([ClinicalTrials.gov](ClinicalTrials.gov)) |  | ARTICLE HISTORY\u003Cbr>Received 5 September 2025 Accepted 23 December 2025\u003Cbr>KEYWORDS\u003Cbr>MDX2001; advan","cbCaifzWbtn38B1G","https://ap.wps.com/l/cbCaifzWbtn38B1G","pdf",1097137,"English","# Abstract\n# Plain language summary\n# Background and rationale\n# Article information and registration\n# Supplemental and publication information","[{\"question\":\"What is MDX2001 and how does it work?\",\"answer\":\"MDX2001 is a tetraspecific T-cell engager-expander antibody designed to bind c-MET and TROP2 on tumor cells, CD3 to activate T cells, and CD28 to support T-cell survival and proliferation.\"},{\"question\":\"What is the purpose of the MDX-2001–101 trial?\",\"answer\":\"The trial protocol evaluates the safety, tolerability, and antitumor effects of MDX2001 monotherapy in patients with advanced solid tumors.\"},{\"question\":\"How are the trial phases organized (phase Ia, Ib, and IIa)?\",\"answer\":\"Phase Ia uses Bayesian-guided dose escalation to determine dosing for further study. Phase Ib expands dosing across up to two doses and multiple solid tumor types, and Phase IIa tests effects in patients at the selected doses and tumor types.\"}]","MDX-2001–101 study protocol - a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors | PDF",1790115271,[145],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/f3c543752a64aa5fc94a178825ac08f6.webp",983,1280]